At Alkahest, we are decoding the plasma proteome to discover key proteins that increase or decrease with age, which we call chronokines. We then interrogate the chronokines to find those which act as key checkpoint nodes of biological aging, whether driving beneficial pathways like homeostasis, tissue repair, neural functioning and stem cell regeneration, or those detrimental pathways that cause tissue damage, inflammation, and neurodegeneration.
From those with the most impact on biological function, we create transformative therapies that halt or reverse the harmful effects of aging in critical diseases and alleviate their devastating consequences afflicting patients around the world. Our simple, elegant approach capitalizes on the body’s natural regulatory and communication mechanism: the plasma proteome.
The potential influence of chronokines in diseases of aging has inspired our therapeutic approach, which has so far delivered three candidates into Phase II clinical trials. In preclinical studies, Alkahest scientists demonstrated that our therapeutic targets activate molecular signaling pathways in older animals that include increased tissue regeneration, reduced age-related cognitive impairment, reduced neuroimmune activation, increased memory function.
Our current clinical trials are testing our therapeutic approaches for a range of age-related medical conditions, including Alzheimer’s disease, Parkinson’s disease, Age-Related Macular Degeneration, post-surgical recovery and others.